The relationship between epidermal growth factor receptor (EGFR) mutation status and EGFR-tyrosine kinase inhibitors (TKI)
efcacy in non-small cell lung cancer (NSCLC) patients has been well established. However, there is no available standard to
define the optimal testing method and specimen type required for the detection of EGFR mutations. In this study, we compare results of ADx-amplification refractory mutation system (ARMS) and direct sequencing for the detection of EGFR mutation and prediction of EGFR-TKI efficacy for surgery and biopsy tumor tissues in 158 NSCLC patients.
Med Oncol (2014) 31:926; DOI 10.1007/s12032-014-0926-3
Though the possibility of using malignant pleural effusions (MPEs) as alternatives for metastatic pleural tumor tissues (MPTTs) in epidermal growth factor receptor (EGFR) mutation test has been examined, due to the lack of studies comparing the results in matching MPEs and MPTTs, the clinical value of MPEs for advanced adenocarcinoma patients with pleural effusions is not
PLOS ONE, February 2014, Volume 9, Issue 2, e89946
Compared with FISH and qRT-PCR analyses, immunohistochemistry (IHC) is the preferred screening test in most pathology
practices for ALK-rearrangement detection. With 100% sensitivity and 98% specificity, the VENTANA ALK (D5F3) IHC assay has been approved in the EU and some Asian countries for ALK-rearrangement detection. However, an automated Ventana IHC
platform is not available in most pathology labs. In this study, we evaluated the applicability of conventional IHC with D5F3
antibody in routine pathological practice and proposed detection methods and procedures that ensure that patients withALK+ are not missed.
Diagnostic Pathology 2014, 9:3. http://www.diagnosticpathology.org/content/9/1/3
Activating mutations of epidermal growth factor receptor (EGFR) could predict response to tyrosine kinase inhibitor(TKI)
treatment in patients with non-small cell lung cancer (NSCLC). However, the detection of EGFR mutation is frequently
challenging in clinical practice for the lack of tumor tissue.The aim of this study was to investigate the feasibility of performing EGFR mutation testing on various types of liquid-based cytology (LBC) samples.
Asian Pacifc Journal of Cancer Prevention, Vol 15, 2014
棘皮动物微管相关样蛋白4 ( echinoderm microtubule associated protein-like 4 , EML4）与间变性淋巴瘤激酶(anaplastic lymphoma kinase，ALK)融合基因是非小细胞肺癌（NSCLC）中继表皮生长因子受体（EGFR）突变、KRAS突变后的又一特异性肿瘤驱动基因，近期，针对EML4-ALK为靶点的克哩替尼（crizotinib）在治疗晚期NSCLC中已取得了令人瞩目的疗效，因此使用准确、可靠且易于临床开展的EML4-ALK融合基因检测方法是决定患者能否应用克哇替尼治疗的先决条件。2013年3月，基于逆转录聚合酶链反应（RT-PCR）技术的国产EML4-ALK检测试剂盒获得中国食品药品监督管理总局（CFDA）批准上市。本文主要介绍RT-PCR技术在EML4-ALK融合基因筛查中的应用。
中华病理学杂志 2013年12月第42卷第12期（Chin J Pathol , December 2013 , Vol.42, No.12）
中华病理学杂志 2013年4月第42卷第4期（Chin J Pathol, April 2013, Vol.42, No.4）